Together, We Can Transform the Future of Colorectal Cancer Care
Despite colorectal cancer being the second leading cause of cancer death globally, research into the disease is underfunded. As an MSK Giving donor, you make a lifesaving difference by supporting trailblazing experts in colorectal cancer research and care, bringing hope to patients and their families.
Your support fuels breakthroughs
Thanks to donors, MSK is a leader in colorectal cancer research and care. U.S. News & World Report ranked us as the #2 cancer hospital in the country, and Charity Navigator gave us its highest rating.
We’ve made considerable progress in colorectal cancer research
With your support, MSK has made strides in new treatments and cures:
- A groundbreaking rectal cancer immunotherapy clinical trial with a 100% success rate that led to an FDA-designated Breakthrough Therapy.
- The first FDA-approved colorectal cancer treatment that targets the KRAS gene.
- And many more innovative advances that are improving — and saving — lives.
And we’re creating even more hope for tomorrow
Oncologists across the globe are alarmed by the rising rates of colorectal cancer in people under 50. Doctors and researchers at MSK’s Center for Young Onset Colorectal and Gastrointestinal Cancer — the first clinic in the world of its kind — are working to better understand why, and provide unparalleled care tailored to the specific needs of these patients.
Fund the next discovery in colorectal cancer research and care. You can also donate in honor or memory of a loved one.
Defying a trillion to one odds starts with you
Your gift today can power the next big breakthrough
With your support, MSK can continue leading the way forward in colorectal cancer research and care. Learn more about MSK’s innovations and advances and the progress you fuel as an MSK Giving donor.
Accelerating new therapies
The FDA granted accelerated approval to a new drug based on a clinical trial led by MSK’s Alexander Drilon, MD. The drug, repotrectinib, targets gene changes called NTRK fusions, which can be found in some colorectal cancers.
Learn moreAnswering the biggest questions
MSK’s Center for Young Onset Colorectal and Gastrointestinal Cancer is dedicated to understanding the puzzling rise of new diagnoses in people under 50 — while also meeting the specific needs of these patients with personalized care.
Get more informationTargeting cancer with vaccines
MSK’s Eileen O’Reilly, MD, helped lead a clinical trial that showed promising results for an off-the-shelf vaccine for people with colorectal cancers that have certain KRAS mutations.
Read moreStopping cancer before it starts
People with Lynch syndrome, a genetic condition, are at increased risk of developing colorectal cancer. MSK doctors are researching whether immunotherapy can be used preventively to protect higher-risk individuals against cancer.
Learn morePioneering surgical techniques
MSK surgeons are experts in using robot-assisted surgery to treat people with colorectal cancer, performing more than 700 operations each year.
See moreTransform the future of colorectal cancer care worldwide.
